This heterogeneity has driven the search for additional biomarkers of efficacy beyond PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI), all of which provide only partial predictive accuracy. The gene discussed is CD274; the disease is neoplasm.